公开(公告)号：US20180264038A1

公开(公告)日：2018-09-20

申请号：US15764187

申请日：2016-09-28

Applicant: Regents of the University of Minnesota

Inventor： Bruce R. Blazar ,  Ryan P. Flynn ,  Christopher A. Pennell

IPC: A61K35/17 ,  C07K16/28 ,  A61K48/00 ,  A61K9/00

CPC classification number: A61K35/17 ,  A01K2207/15 ,  A01K2227/105 ,  A01K2267/0387 ,  A61K9/0019 ,  A61K48/005 ,  A61P37/06 ,  C07K16/2803 ,  C07K2317/622 ,  C07K2319/03 ,  C07K2319/33 ,  C12N2740/10043

Abstract: Provided herein are methods and materials for treating autoimmune diseases and alloimmune diseases. Specifically, provided are a pharmaceutical composition comprising a therapeutically effective amount of a population of modified human T cells, wherein the human T cells are modified to comprise a nucleic acid sequence that encodes a chimeric antigen receptor (CAR) construct, wherein the CAR construct comprises an antigen binding domain, wherein the antigen binding domain is specific for a ligand expressed on B cells, plasma cells or plasmablasts in human patients suffering from an autoimmune disease or an alloimmune disease; and a method of treating an autoimmune or an alloimmune disease in a human patient, the method comprising: administering a pharmaceutical composition.